Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)

Authors

Jonathan Cohen (ORCID: https://orcid.org/0000-0003-1743-836X)
Kathryn Mahoney
Myra Popejoy
Deepali Gupta (ORCID: https://orcid.org/0000-0002-6771-2534)
Ilker Yalcin
Kristin Narayan (ORCID: https://orcid.org/0000-0002-7977-4783)
Ed Campanaro
Natalia Betancourt
Anna Holmes
Peter Schmidt (ORCID: https://orcid.org/0000-0002-8664-3706)
Pamela Hawn
Cameron R. Wolfe (ORCID: https://orcid.org/0000-0002-5365-5030)
Anne-Marie Phelan
Yong Li
Mark A. Wingertzahn
Claudio Katz
Kazima Tosh

Institutions

Duke University (US)
BG Medicine (United States) (US)
InVivo Analytics (United States) (US)

Publication Details

Journal: Clinical Infectious Diseases
Published: 2025-05-23
DOI: https://doi.org/10.1093/cid/ciaf265
Citations: 8
Primary Topic: SARS-CoV-2 and COVID-19 Research
Type: article
Field-Weighted Citation Impact: 11.17

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)

Jonathan Cohen, Kathryn Mahoney, Myra Popejoy, Deepali Gupta et al.

May 23, 2025

8 citations

Clinical Infectious Diseases

SARS-CoV-2 and COVID-19 Research

11.17

article

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)

Jonathan Cohen, Kathryn Mahoney, Myra Popejoy, Deepali Gupta, Ilker Yalcin, Kristin Narayan, Ed Campanaro, Natalia Betancourt, Anna Holmes, Peter Schmidt, Pamela Hawn, Cameron R. Wolfe, Anne-Marie Phelan, Yong Li, Mark A. Wingertzahn, Claudio Katz, Kazima Tosh

May 23, 2025article en

8 citations

Abstract

No abstract available for this paper.

Clinical Infectious DiseasesVol. 81(3)

Duke University (US), BG Medicine (United States) (US), InVivo Analytics (United States) (US)

Good health and well-being

Openalex Percentile: Top 1%

SARS-CoV-2 and COVID-19 Research

11.17

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.